Startup Sensation: T2S Group Ignites Casablanca Market with $110M IPO

Daba Finance/T2S Group Holding has officially launched its Initial Public Offering (IPO) on the Casablanca Stock Exchange, marking the opening of Morocco’s 2026 IPO market with a substantial deal valued at up to 1.1 billion dirhams, approximately $110 million. This significant offering reflects a continued recovery and robust investor interest in Morocco's equity market, following a strong return of public listings in 2025.

Founded in 1992, T2S Group is a prominent player in the African healthcare technology sector. The company specializes in supplying essential medical equipment, advanced diagnostic systems, radiopharmaceutical products, and comprehensive hospital software. Operating through four subsidiaries and employing over 400 people, T2S partners with more than 40 international medical technology companies, including industry giant GE Healthcare. Its extensive reach spans over 20 African countries, establishing it as a key provider across the continent.

The IPO, which received approval from Morocco’s capital markets regulator, commenced its subscription period from July 13 to July 17, with trading expected to begin on July 27 under the ticker T2S. The offering comprises a capital increase of nearly 350 million dirhams alongside the sale of approximately 750 million dirhams of existing shares. A total of 4.93 million shares are being offered at 223 dirhams each, valuing the entire business at about 4.86 billion dirhams. Post-offering, the free float will represent around 22.6% of the company, with existing controlling shareholders remaining subject to lock-up agreements.

T2S Group has demonstrated strong financial performance, reporting revenue of 1.76 billion dirhams and a net profit of 211 million dirhams in 2025. The company projects ambitious growth, with expected revenue reaching 4.17 billion dirhams and net profit climbing to 607 million dirhams by 2030.

The proceeds from this IPO are earmarked for strategic expansion and operational enhancements. Key investments include funding a second cyclotron facility in Fez, rolling out new diagnostic equipment, upgrading information technology systems, and fortifying cybersecurity infrastructure. Furthermore, T2S has outlined significant expansion plans, including new oncology projects in Côte d’Ivoire, Mali, and Senegal, alongside continuous growth in its diagnostics and after-sales services segments. These initiatives underscore the company's commitment to capitalizing on the rising demand for medical equipment, diagnostics, and cancer treatment across Africa.

T2S Group stands out in the healthcare distribution landscape due to its integrated business model. Unlike many distributors, it combines equipment sales with crucial maintenance services, digital hospital systems, and radiopharmaceutical production, thereby creating several reliable sources of recurring revenue. This comprehensive approach positions T2S to benefit significantly from the expansion of healthcare capacity by governments and private providers throughout Africa.

For investors, the primary consideration will be T2S's ability to achieve its aggressive growth targets while meticulously maintaining margins as it ventures into new markets and increases capital expenditure. The IPO also reinforces Casablanca’s reputation as one of Africa’s most active stock exchanges for new listings. Following the strong investor demand for SGTM, Vicenne, and Cash Plus in 2025, the T2S offering will serve as a crucial test of whether this momentum can be sustained into 2026 and if Morocco’s IPO market can support a broader pipeline of large private companies seeking public capital.